Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes
Provention Bio, Inc. (NASDAQ:NASDAQ:PRVB) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Robert Doody - Vice President, Investor Relations Thierry Chauche -.
Science for just $15 USD.
Prolonged prevention of autoimmune diabetes
Teplizumab was previously shown in a clinical trial to delay onset of type 1 diabetes (T1D) in high-risk relatives of individuals with T1D. Now, Sims
et al. extend the follow-up analysis of this trial by 12 months, finding that efficacy of the initial 2-week treatment course persisted, with an extended time to T1D diagnosis in the teplizumab-treated group. Clinical benefits associated with reversed C-peptide decline improved beta cell function and partial exhaustion in CD8
+ T cells in the treated patients. HbA1c did not differ between placebo and treatment groups. This follow-up study further supports the use of anti-CD3 treatment for the prevention of T1D.
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals sciencemag.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencemag.org Daily Mail and Mail on Sunday newspapers.